- Home
- SPRY
as 01-17-2025 4:00pm EST
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.1B | IPO Year: | N/A |
| Target Price: | $26.00 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.00 - $18.51 | Next Earning Date: | 11-13-2024 |
| Revenue: | $2,568,000 | Revenue Growth: | 8460.00% |
| Revenue Growth (this year): | 66750% | Revenue Growth (next year): | 508.63% |
Stock Insider Trading Activity of ARS Pharmaceuticals Inc. (SPRY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Shawver Laura | SPRY | Director | Jan 6 '25 | Sell | $11.10 | 50,000 | $555,065.00 | 210,346 | |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Dec 17 '24 | Sell | $11.67 | 100,000 | $1,167,100.00 | 1,297,447 | |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Dec 17 '24 | Sell | $11.67 | 100,000 | $1,167,100.00 | 1,098,499 | |
| Chakma Justin | SPRY | Chief Business Officer | Dec 12 '24 | Sell | $12.16 | 144,605 | $1,768,092.94 | 136,380 | |
| Dorsey Brian | SPRY | Chief Operating Officer | Dec 11 '24 | Sell | $12.36 | 40,000 | $493,858.50 | 6,024 | |
| Lowenthal Richard E | SPRY | PRESIDENT AND CEO | Dec 10 '24 | Sell | $13.16 | 100,000 | $1,316,420.00 | 1,297,447 | |
| Tanimoto Sarina | SPRY | CHIEF MEDICAL OFFICER | Dec 10 '24 | Sell | $13.16 | 100,000 | $1,316,420.00 | 1,098,499 | |
| Chakma Justin | SPRY | Chief Business Officer | Dec 10 '24 | Sell | $13.15 | 50,000 | $657,625.00 | 136,380 | |
| Chakma Justin | SPRY | Chief Business Officer | Dec 4 '24 | Sell | $14.11 | 144,640 | $2,041,200.04 | 136,380 | |
| Karas Eric | SPRY | Chief Commercial Officer | Dec 2 '24 | Sell | $14.06 | 10,000 | $140,423.37 | 5,693 |
Latest ARS Pharmaceuticals Inc. News
SPRY Breaking Stock News: Dive into SPRY Ticker-Specific Updates for Smart Investing
Investor's Business Daily
5 days ago
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Simply Wall St.
5 days ago
Exploring Three High Growth Tech Stocks In The United States
GlobeNewswire
5 days ago
ARS Pharmaceuticals Announces Preliminary Fourth Quarter 2024 Financial Results and 2025 Objectives for neffy® (epinephrine nasal spray)
TipRanks
11 days ago
ARS Pharmaceuticals files for approval of neffy in Canada, U.K.
Medical Device Network
11 days ago
ARS Pharma seeks approval for epinephrine spray in Canada and UK
MT Newswires
12 days ago
ARS Pharmaceuticals Files for Approval of Experimental Allergic Reaction Treatment in Canada, UK
GlobeNewswire
12 days ago
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S
Simply Wall St.
16 days ago
Top US Growth Companies With Insider Ownership In January 2025
Compare SPRY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SPRY ARS Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.